Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG AGM Information 2009

Jun 25, 2009

291_ip_2009-06-25_b633511a-0d13-432c-8786-b54d1bfdcf82.pdf

AGM Information

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

AnnualShareholders' Meeting 2009

Munich, May 13, 2009

Convenience Translation – The spoken word shall prevail

Operational Review 2008

Financial Review 2008 & Q1 2009

Outlook 2009

Information on the Agenda

Questions & Answers

Voting

Operational Progress in 2008

Strengthened Management Board Dr Arndt Schottelius (MD)

  • Appointment as Chief Development Officer in December 2008
  • Joined MorphoSys from biotechnology pioneer Genentech/USA:
  • Directed early clinical development programs
  • Directed late-stage development studies (Rituximab and Ocrelizumab)
  • Further Positions:
  • Berlex Biosciences, California, USA
  • Schering AG, Berlin, Germany
  • Research Fellowship at the University of North Carolina, Chapel Hill, USA
  • Charité University Hospital, Berlin, Germany
  • PhD and MD degrees from the Albert-Ludwigs-University, Freiburg, Germany Dr. Schottelius is heading the

preclinical and clinical activities of MorphoSys

Two Successful Business Segments

Value Through Strong Partnerships

Partnered Pipeline 55 Programs Ongoing*

N
a
m
e		 P
t
a
r
n
e
r		 i
i
I
d
t
n
c
a
o
n		 i
D
s
c
o
v
e
r
y		 i
i
P
l
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
G
b
t
a
n
e
n
e
r
u
m
a
(
R
1
4
0
)
5		 R
h
o
c
e		 A
l
h
i
e
m
e
r
z
B
H
Q
8
8
0		 N
i
t
o
v
a
r
s		 C
a
n
c
e
r
d
n.		 C
t
e
n
o
c
o
r		 I
l
m
m
n
o
o
g
u
y
/
C
a
n
c
e
r
P
d
2
9
t
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
s
u		 V
i
**
a
r
o
s
u		 A f
D
b
s
o
e
c
e
m
e		 3
1,
2
0
0
7
r
2
2
P
d
t
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
u
s		 V
i
**
a
r
o
u
s		 D l
i
t
e
v
e
o
p
m
e
n		 2
0
0
8
n

* As of December 31, 2008

** Indications include cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases

Ongoing Progress in the Partnered Pipeline*

* As of December 31, 2008

Proprietary Product Pipeline: Three Programs Ongoing*

N
a
m
e		 P
t
a
r
n
e
r		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
v
e
r
y		 P
l
i
i
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
M
O
R
1
0
3		 – R
h
i
d
t
e
m
a
o
u
A
h
i
i
t
t
r
r
s		 P
r
o		 i
P
t
p
r
e
a
r
r
o
y		 g
r
a
m
s
3
O
M
R
2
0
2		 – C
a
n
c
e
r		 2
d
n.		 M
h
S
/
o
r
p
o
y
s
N
i
t
o
v
a
r
s		 d
n.		 2
0		 0
7		 2
0
0
8
*
A
f
D
s
o
e		 b
3
1,
2
0
0
8
c
e
m
e
r

MOR103: Promising Product Candidate

  • Successful completion of phase 1 in healthy volunteers
  • Based on favorable safety profile trial was extended
  • In total, 7 cohorts (63 volunteers) were treated
  • Promising scientific and preclinical data
  • Broad patent protection for MOR103 in the US

Page 10

Further Proprietary Activities

HuCAL PLATINUMThe Next Generation

G
O
L
D		 P
L
A
T
I
N
U
M
S
L
i
b
i
r
a
r
e
y
z		 1
2
b
i
l
l
i
o
n		 4
b
i
l
l
i
5
o
n
U
d
l
i
D
b
t
n
e
r
y
n
g
a
a
a
s
e		 1
9
9
7		 2
0
0
8
D
i
i
f
I
l
d
A
i
b
d
i
t
t
t
e
r
s
o
s
o
a
e
n
o
e
s
v
y		 1
x		 2
5
x
A
f
f
i
i
i
t
n
e
s		 1
x		 4
x
P
d
i
i
t
t
r
o
u
c
v
y		 1
x		 3
x

HUCAL - A Commercial Success

  • More than 50 active therapeutic programs
  • More than 1,000 research antibody projects concluded
  • More than € 200 million generated
  • Royalties on HuCAL GOLD-based products still to come

Two Successful Business Segments

AbD Serotec: Successful Despite Strong Headwinds

Operational Review 2008

Financial Review 2008 & Q1 2009

Outlook 2009

Information on the Agenda

Questions & Answers

Voting

Consolidated Statements of Operations (Group) 2008

I
€
i
l
l
i
n
m
o
n
s		 2
0
0
8		 2
0
0
7
R
e
v
e
n
u
e
s		 7
1
6		 6
2
0
C
f
G
d
S
l
d
(
C
O
G
S
)
t
o
s
o
o
o
s
o		 7
1		 7
9
R
&
D
E
p
e
n
s
e
s
x		 2
6
7		 2
2
2
S
G
&
A
E
x
p
e
n
s
e
s
,		 2
0
5		 2
4
8
i
T
l
O
E
t
t
o
a
p
e
r
a
n
g
x
p
e
n
s
e
s		 5
5
2		 5
4
9
f
i
f
i
P
O
t
t
r
o
r
o
m
p
e
r
a
o
n
s		 1
6
4		 7
0
*
O
N
i
I
t
o
n
p
e
r
a
n
g
n
c
o
m
e
-		 1
6		 2
2
f
i
f
P
b
T
t
r
o
e
o
r
e
a
x
e
s		 1
8
0		 9
2
I
T
n
c
o
m
e
a
x
e
s		 (
)
4
8		 2
3
N
P
f
i
t
t
e
r
o		 1
3
2		 1
1
5
S
(
)
E
i
h
d
i
l
d
i
€
t
a
r
n
n
g
s
p
e
r
a
r
e
e
n
u		 0
9
5		 0
3
5

* Differences due to rounding

MorphoSys AG - Annual Shareholders' Meeting - May 13, 2009

Therapeutic Antibodies Segment Revenues

Funded Research Increase of 7 % to € 16.7 million

License Fees

Nearly doubled in comparison to 2007 to an amount of € 26.8 million (+84 %)

Success-based Payments

Decrease of € 2.2 million (-18 %) compared to previous year

I
€
i
l
l
i
n
m
o
n		 2
0
0
8		 2
0
0
7
R
e
v
e
n
u
e
s		 5
3
4		 4
2
4		 i
T
h
t
e
r
a
p
e
u
c
O
i
E
t
p
e
r
a
n
g
x
p
e
n
s
e
s		 2
8
7		 2
2
7		 i
i
A
b
d
t
n
o
e
s
S
R
l
t
t
e
g
m
e
n
e
s
u		 2
5
6		 1
5
2
I
€
i
l
l
i
n
m
o
n		 2
0
0
8		 2
0
0
7
R
e
e
n
e
s
v
u		 1
8
2		 1
9
6
C
f
G
d
S
l
d
(
C
O
G
S
)
t
o
s
o
o
o
s
o		 7
1		 7
9
P
f
i
G
t
r
o
s
s
r
o		 1
1
1		 1
1
7		 A
b
D
O
i
E
t
p
e
r
a
n
g
x
p
e
n
s
e
s		 1
0
7		 1
2
3
S
R
l
t
t
e
g
m
e
n
e
s
u		 0
4		 (
)
0
6

Expenses for Proprietary Activities

Consolidated Balance Sheet (Group) 2008

I
€
i
l
l
i
n
m
o
n		 /
/
1
2
3
1
2
0
0
8		 /
/
1
2
3
1
2
0
0
7
A
t
s
s
e
s
C
C
h
h
E
i
l
&
A
i
l
b
l
f
t
a
s
a
s
q
a
e
n
s
a
a
e
o
r
u
v
v
-
,
S
l
F
i
i
l
A
t
a
e
n
a
n
c
a
s
s
e
s		 1
3
9
7		 1
0
6
9
O
h
A
t
t
e
r
s
s
e
s		 1
2
2		 1
6
0
C
N
A
t
t
o
n
u
r
r
e
n
s
s
e
s
-		 5
3
2		 6
1
8
T
l
A
t
t
o
a
s
s
e
s		 2
0
3
3		 1
8
4
7
L
i
b
i
l
i
i
t
a
e
s
C
L
i
b
i
l
i
i
t
t
r
r
e
n
a
e
s
u		 2
7
4		 2
9
4
N
C
L
i
b
i
l
i
i
t
t
o
n
u
r
r
e
n
a
e
s
-		 1
3
9		 9
8
S
'
T
l
k
h
l
d
E
i
t
t
t
o
a
o
c
o
e
r
s
q
u
y		 1
6
2
0		 1
4
5
5
T
l
L
i
b
i
l
i
i
t
t
o
a
a
e
s		 2
0
3
3		 1
8
4
7

Shareholder Structure*

3:1 Share Split implemented on December 23, 2008

S
h
I
d
D
b
3
1
2
0
0
8
t
a
r
e
s
s
s
e
a
e
c
e
m
e
r
u
,		 2
2
4
8
8
7
7
7
,
,
N
i
t
ƒ
o
v
a
r
s		 7
%
~
A
Z
t
s
r
a
e
n
e
c
a
ƒ		 5
%
~
f
V
d
d
A
i
h
t
t
t
o
r
s
a
n
u
n
u
s
c
s
r
a
ƒ		 2
5
%
~
S
b
i
t
t
r
e
u
e
s
z		 8
8
%
~

Frankfurt Stock Exchange ISIN: DE0006632003SE Code: MORBloomberg: MOR GR

*As of Dec 31, 2008

Share Price Development 2008

l
E
m
p		 o
y
e
e
s
------------------ -----------------------
2
0
0
8		 2
0
0
7
T
l
E
l
t
o
a
m
p
o
e
e
s
y		 3
3
4		 2
9
5
G
h
i
S
l
i
t
e
o
g
r
a
p
c
p
G
e
r
m
a
n
y		 2
3
6		 1
9
2
U
K		 8
2		 8
3
U
S
A		 1
6		 2
0
S
i
S
l
b
t
t
p
y
e
g
m
e
n
S
T
h
i
t
t
e
r
a
p
e
c
e
g
m
e
n
u		 2
0
1		 1
6
7
A
b
D
S
t
e
g
m
e
n		 1
3
3		 1
2
8

Projected new hires for R&D in 2009: > 40 employees

Consolidated Statements of Operations (Group) Q1 2009

I
€
i
l
l
i
n
m
o
n		 Q
1
2
0
0
9		 Q
1
2
0
0
8
R
e
v
e
n
u
e
s		 1
9
1		 1
6
3
C
f
G
d
S
l
d
(
C
O
G
S
)
t
o
s
o
o
o
s
o		 1
7		 1
7
R
&
D
E
p
e
n
s
e
s
x		 8
5		 3
5
S
G
&
A
E
p
e
n
s
e
s
x
,		 4
8		 5
2
T
l
O
i
E
t
t
o
a
p
e
r
a
n
g
p
e
n
s
e
s
x		 *
1
4
9		 1
2
2
P
f
i
f
O
i
t
t
r
o
r
o
m
p
e
r
a
o
n
s		 4
2		 4
1
O
N
i
I
t
o
n
p
e
r
a
n
g
n
c
o
m
e
-		 0
9		 0
6
P
f
i
b
f
T
t
r
o
e
o
r
e
a
x
e
s		 5
1		 4
7
I
T
n
c
o
m
e
a
e
s
x		 1
6		 1
4
N
P
f
i
t
t
e
r
o		 3
5		 3
3
S
(
)
E
i
h
d
i
l
d
i
€
t
a
r
n
n
g
s
p
e
r
a
r
e
u
e
n		 0
1
6		 0
1
5

* Differences due to rounding

MorphoSys AG - Annual Shareholders' Meeting - May 13, 2009 Page 24

Total Liabilities

Consolidated Balance Sheet (Group) Q1 2009

I
M
i
€
n
o		 /
/
0
3
3
1
2
0
0
9		 /
/
1
2
3
1
2
0
0
8
A
t
s
s
e
s
C
C
h
h
E
i
l
&
A
i
l
b
l
f
t
a
s
a
s
q
a
e
n
s
a
a
e
o
r
u
v
v
-
,
S
l
F
i
i
l
A
t
a
e
n
a
n
c
a
s
s
e
s		 1
3
6
1		 1
3
9
7
O
h
A
t
t
e
r
s
s
e
s		 1
3
4		 1
2
2
C
N
A
t
t
o
n
u
r
r
e
n
s
s
e
s
-		 5
1
8		 5
3
2
T
l
A
t
t
o
a
s
s
e
s		 2
0
1
3		 2
0
3
3
L
i
b
i
l
i
i
t
a
e
s
C
L
i
b
i
l
i
i
t
t
r
r
e
n
a
e
s
u		 2
2
7		 2
4
7
N
C
L
i
b
i
l
i
i
t
t
o
n
u
r
r
e
n
a
e
s
-		 1
2
9		 1
3
9
S
'
T
l
k
h
l
d
E
i
t
t
t
o
a
o
c
o
e
r
s
q
u
y		 1
6
5
7		 1
6
2
0
T
l
L
i
b
i
l
i
i
t
t
o
a
a
e
s		 2
0
1
3		 2
0
3
3

Operational Review 2008

Financial Review 2008 & Q1 2009

Outlook 2009

Information on the Agenda

Questions & Answers

Voting

Critical Success Factors for MorphoSys's Sustainable Growth

Leading antibody technology as source of innovative drugs

Secured revenues > € 400 million through long-term pharma partners

Milestone & royalty potential >> € 1 billion

Investment in proprietary R&D to foster long-term value generation

Strong balance sheet with > € 130 million in cash

Therapeutic Development Activities with Partners

Existing Partnerships are a Major Driver of Future Growth

Proprietary Programs Outlook 2009

Proprietary Product Pipeline: Plan for Year End 2009

N
a
m
e		 P
t
a
r
n
e
r		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
v
e
r
y		 P
l
i
i
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
- R
h
i
d
t
e
m
a
o
u
A
h
i
i
t
t
r
r
s
O
M
R
1
0
3		 M
S
/
R
i
t
e
s
p
r
a
o
r
y
D
i
s
e
a
s
e
s
O
M
R
2
0
2		 - C
a
n
c
e
r
M
O
R
2
0
3		 - C
a
n
c
e
r		 U
t
7
p
o		 P
i
t
r
o
p
r
e
a
r
y
M
O
R
2
0
5		 - C
a
n
c
e
r		 P
r
o
g
r
a
m		 s
O
M
R
x
x
x		 - d
n.
M
O
R
x
x
x		 - d
n.
M
O
R
x
x
x		 - d
n.
d
n.		 N
i
t
o
v
a
r
s		 d
n.		 1
P
d
r
e
e
v
P
r
o
g
r
a
m		 l
t
e
o
p
m
e
n

GOAL:

Substantial Proprietary Product Pipeline, based on HuCAL Technology

Clinical Pipeline Plan for Year End 2009

The Clinical Antibody Pipeline is the Future Value Driver

AbD Serotec: Outlook

2 – 4 INDs

20 new program starts

Phase 1 data & start of a phase 2 RA study

Up to 5 new programs (Cancer & Inflammation) Revenues in the amountof approx. € 20 million

Profit margin at least as high as in 2008

Future Value Creation

Operational Review 2008

Financial Review 2008 & Q1 2009

Outlook 2009

Information on the Agenda

Questions & Answers

Voting

    1. Formal approval on behalf of the Board of Management
    1. Formal approval on behalf of the Supervisory Board
    1. Appointment of the auditors for the business year 2009
    1. Increase and amendment of the Conditional Capital 2008-II in sec. 5 para. 6 d of the Articles; amendment of the Articles
    1. Deletion of the Conditional Capital 1998-I and partial deletion of the Conditional Capital 1999-I, amendment of the Articles
    1. Resolution on the authorization to issue option rights to employees and to members of the board of management, creation of a new conditional capital and amendment of the Articles
    1. Compensation of the Supervisory Board
    1. Execution of the shareholders' resolutions

Annual Shareholders' Meeting 2009

MorphoSys would like to thank all shareholders!

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, AutoCAL®, CysDisplay®, Agx® and RapMAT® are registered trademarks of MorphoSys AG

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →